Alnylam Pharmaceuticals Stock Forecast NASDAQ:ALNY

Price Target and Analyst Ratings

Most Recent Rating

On August 27, 2021 "BMO Capital Markets" gave "$174.00 - $196.00" rating for ALNY. The price target was set to $207.63+2.6%.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-08-27	$174.00 - $196.00	Target Raised by	BMO Capital Markets	$203.93	$207.63+2.6%
2021-08-13	$235.00 - $250.00	Target Raised by	HC Wainwright	$196.54	$200.92→1.0%
2021-08-04	$190.00	Reiterated by	Chardan Capital	$183.44	$182.33+2.0%
2021-08-04	$224.00 - $234.00	Target Raised by	Morgan Stanley	$183.44	$178.81+0.5%
2021-08-04	$196.00 - $216.00	Target Raised by	Barclays	$183.44	$178.81+0.5%
2021-08-04	$45.00 - $47.00	Downgraded by	Piper Sandler	$183.44	$178.81+0.5%
2021-07-16	$205.00 - $224.00	Target Raised by	Morgan Stanley	$177.54	$173.67+1.0%
2021-05-06	Overweight	Target Lowered by	Morgan Stanley	$132.10	$206.00 → $205.00
2021-04-30	Overweight	Target Lowered by	Morgan Stanley	$140.64	$206.00 → $205.00
2021-04-30	Overweight	Target Lowered by	Morgan Stanley	$140.64	$206.00 → $205.00
2021-04-20	Buy	Reiterated by	Needham & Company LLC	$136.03
2021-03-01	Buy - Neutral	Reiterated by	Guggenheim	$148.75	$162.00
2021-02-22	Buy - Neutral	Downgraded by	Guggenheim	$148.07
2021-02-22	Buy - Neutral	Downgraded by	Guggenheim	$148.07	$162.00
2021-02-14	Hold	Reiterated by	Royal Bank of Canada	$157.92
2021-02-12	Buy	Target Raised by	Needham & Company LLC	$157.92	$160.00 → $180.00
2021-02-12	Overweight	Target Raised by	Morgan Stanley	$157.92	$203.00 → $206.00
2021-02-12	Buy	Target Raised by	HC Wainwright	$157.92	$225.00 → $235.00
2021-02-12	Buy - Neutral	Downgraded by	Citigroup	$157.92	$170.00 → $175.00
2021-02-12	Overweight	Target Raised by	Barclays	$157.92	$162.00 → $196.00
2021-02-12	Buy	Reiterated by	HC Wainwright	$157.92	$225.00 → $235.00
2021-01-25	Outperform - Market Perform	Downgraded by	BMO Capital Markets	$175.69	$185.00
2021-01-13	In-Line - Outperform	Target Raised by	Cowen	$170.93	$154.00 → $197.00
2021-01-08	Buy	Reiterated by	HC Wainwright	$146.66	$225.00
2020-12-21	Sector Perform	Target Lowered by	Royal Bank of Canada	$139.43	$150.00 → $144.00
2020-12-17	Overweight	Target Raised by	Piper Sandler	$138.65	$169.00 → $181.00
2020-12-17	Overweight	Reiterated by	Piper Sandler	$138.65	$169.00 → $181.00
2020-11-25		Target Raised by	BMO Capital Markets	$125.45	$182.00 → $183.00
2020-11-25	Overweight	Target Raised by	Morgan Stanley	$125.45	$200.00 → $203.00
2020-11-24	Market Perform	Target Raised by	SVB Leerink	$125.66	$90.00 → $91.00
2020-11-06	Overweight	Target Raised by	Morgan Stanley	$130.73	$197.00 → $200.00
2020-10-15	Buy	Target Lowered by	Bank of America	$143.94	$160.00 → $157.00
2020-10-12	Buy	Reiterated by	Chardan Capital	$147.00
2020-09-30	Hold	Reiterated by	Oppenheimer	$145.60	$156.00
2020-09-30	Hold	Initiated by	Berenberg Bank	$145.60
2020-09-08	Buy	Initiated by	Citigroup	$122.99	$170.00 → $170.00
2020-08-11	Outperform - Market Perform	Downgraded by	Oppenheimer	$136.61	$162.00 → $156.00
2020-08-07	Market Perform	Target Raised by	SVB Leerink	$143.53	$89.00 → $90.00
2020-08-07	Buy	Reiterated by	Chardan Capital	$143.53
2020-08-07	Overweight	Target Lowered by	Morgan Stanley	$143.53	$199.00 → $197.00
2020-07-20	Outperform	Target Raised by	BMO Capital Markets	$165.49	$173.00 → $196.00
2020-07-15	Overweight	Target Raised by	Morgan Stanley	$158.02	$162.00 → $199.00
2020-05-28	Neutral	Target Raised by	UBS Group	$133.10	$111.00 → $122.00
2020-05-12	Sector Perform	Initiated by	Royal Bank of Canada	$144.19
2020-05-07	Overweight	Target Raised by	Barclays	$141.45	$143.00 → $156.00
2020-05-07	Outperform	Target Raised by	BMO Capital Markets	$141.45	$145.00 → $171.00
2020-05-07	Outperform	Target Raised by	Oppenheimer	$141.45	$140.00 → $162.00
2020-05-07	Overweight - Neutral	Downgraded by	JPMorgan Chase & Co.	$141.45	$133.00 → $137.00
2020-05-07	Overweight	Target Raised by	Morgan Stanley	$141.45	$148.00 → $162.00
2020-05-06	Buy	Target Raised by	Needham & Company LLC	$145.27	$135.00 → $160.00
2020-04-14		Target Raised by	Cantor Fitzgerald	$120.72	$195.00 → $202.00
2020-04-14		Target Lowered by	Piper Sandler	$120.72	$147.00 → $142.00
2020-04-14	Buy	Reiterated by	Needham & Company LLC	$120.72	$135.00
2020-04-14	Reduce	Target Lowered by	Nomura	$120.72	$75.00 → $74.00

ALNY Stock Trend

The stock lies in the lower part of a wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $187.30 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift.

Given the current short-term trend, the stock is expected to rise 16.71% during the next 3 months and, with a 90% probability hold a price between $218.59 and $257.67 at the end of this 3-month period.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-20	$187.80	$204.54	$221.28
2021-09-21	$188.30	$205.04	$221.78
2021-09-22	$188.80	$205.54	$222.28
2021-09-23	$189.30	$206.04	$222.78
2021-09-24	$189.80	$206.54	$223.28
2021-09-27	$190.31	$207.05	$223.78
2021-09-28	$190.81	$207.55	$224.29
2021-09-29	$191.31	$208.05	$224.79
2021-09-30	$191.81	$208.55	$225.29
2021-10-01	$192.31	$209.05	$225.79
2021-10-04	$192.81	$209.55	$226.29
2021-10-05	$193.32	$210.06	$226.79
2021-10-06	$193.82	$210.56	$227.30
2021-10-07	$194.32	$211.06	$227.80
2021-10-08	$194.82	$211.56	$228.30
2021-10-11	$195.32	$212.06	$228.80
2021-10-12	$195.82	$212.56	$229.30
2021-10-13	$196.33	$213.07	$229.81
2021-10-14	$196.83	$213.57	$230.31
2021-10-15	$197.33	$214.07	$230.81
2021-10-18	$197.83	$214.57	$231.31
2021-10-19	$198.33	$215.07	$231.81
2021-10-20	$198.83	$215.57	$232.31
2021-10-21	$199.34	$216.08	$232.82
2021-10-22	$199.84	$216.58	$233.32
2021-10-25	$200.34	$217.08	$233.82
2021-10-26	$200.84	$217.58	$234.32
2021-10-27	$201.34	$218.08	$234.82
2021-10-28	$201.84	$218.58	$235.32
2021-10-29	$202.35	$219.09	$235.83

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The companys clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!